Lv43
490 积分 2022-07-20 加入
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
1天前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
1天前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
21天前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
21天前
已完结
Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
22天前
已完结
A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma
27天前
已关闭
Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed/refractory T-ALL: a phase I trial
27天前
已完结
Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed/refractory T-ALL: a phase I trial
27天前
已完结
γδ T cells for cancer immunotherapy: A 2024 comprehensive systematic review of clinical trials
1个月前
已完结
Human γδ T cells in the tumor microenvironment: Key insights for advancing cancer immunotherapy
1个月前
已完结
皖公网安备34019202002308
